Tech Company Financing Transactions

Sparrow Pharmaceuticals Funding Round

Forbion Capital Partners, RA Capital Management and OrbiMed participated in a $95 million Series B capital raise for Sparrow Pharmaceuticals. The round was announced on 9/24/2025.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

920 SW 6th Ave. 1200
Portland, OR 97204
USA

Phone

617-465-0328

Website

www.sparrowpharma.com

Email Address

[email protected]

Overview

Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess. We are developing novel therapies to address the key limitations of treatments for endogenous Cushing's syndrome (Cushing's), autonomous cortisol secretion (ACS), and polymyalgia rheumatica (PMR).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Robert Jacks

        

Chief Scientific Officer

David Katz

        

Vice President

Jeffrey Drajesk

        

Browse more venture capital transactions:

Prev: 9/24/2025: Signal AI venture capital transaction
Next: 9/24/2025: Moneta Health venture capital transaction

Share this article

Where The Data Comes From

We document every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary